Michael Potente is a cardiologist and blood vessel researcher. He arrived at the BIH from the Max Planck Institute for Heart and Lung Research just a few months ago, and is now moving into his new laboratory in the recently opened Käthe Beutler Building on Campus Berlin Buch. There he will conduct research at the BIH & MDC Center for Vascular Biomedicine. “Even in these turbulent times, we have been working vigorously on our major project to better understand blood vessels,” explains the Professor of Vascular Biomedicine. “Blood vessels are everywhere in the body, and they also play a key role in many illnesses.”
Normally, blood vessels in the adult body are in a stable resting state. New vascular capillaries sprout only rarely, for example, during the female menstrual cycle, wound healing or during pathological processes such as tumor growth. The signals that stimulate the endothelial cells to divide are largely known. “We wanted to understand instead what keeps endothelial cells in a dormant state – also known as quiescence,” says Michael Potente.
The scientists from his team already had a good idea where to look: “There are factors that prevent cells from proliferating. One such factor is FOXO1, which controls the transcribing of genetic information in cells; if we switch off FOXO1 in endothelial cells, this leads to excessive vessel growth. Conversely, we can stop blood vessel formation by specifically switching on this factor. We wanted to find out how exactly FOXO1 does this,” explains Jorge Andrade, one of the three lead authors of the paper.
S-2-hydroxyglutarate as “endothelial calming factor”?
To do this, the scientists transferred a continuously active form of FOXO1 into endothelial cells. This caused the endothelial cells to stop dividing and remain in a state of inactivity. To find out how FOXO1 does this, the researchers investigated the metabolism of the cells. For this purpose, they isolated all metabolic products from the cells, which are also known as metabolites. “In this process, we saw that the concentration of 2-hydoxyglutarate, in particular, increased due to FOXO1. This metabolite has already become very well known in cancer medicine,” reports Ana Costa, another lead author of the paper. However, the researchers found that this is a special form of 2-hydroxyglutarate called S-2-hydroxyglutarate. “This variant differs in structure and function from the metabolite produced in some cancer cells,” Costa says.
To confirm the role of S-2-hydroxyglutarate as a possible “endothelial calming factor,” the scientists conducted further experiments on endothelial cells. They added the substance to normal endothelial cells in various concentrations and for different lengths of time. “We observed that S-2-hydroxyglutarate alone is able to keep endothelial cells in a state of quiescence,” explains Chenyue Shi, the third lead author of the paper. Further research showed that S-2-hydroxyglutarate exerts its effect by controlling the transcription of growth-controlling genes. In mouse models, the metabolite also prevented the growth of new vessels, but had no negative effects on existing blood vessels. When the scientists removed S-2-hydroxyglutarate, endothelial cells regained their ability to form new blood vessels.
Targeted influence on blood vessels
“Especially given the fact that ‘too many’ or ‘too few’ new blood vessels play a role in many diseases, it is enormously important for us to better understand the basic mechanisms underlying these processes,” is how Potente summarizes the results. “Our long-term goal is to be able to therapeutically influence the development and function of blood vessels in a targeted manner, and if possible, without any side effects. We have come one step closer to this goal with our work.”
Jorge Andrade, Chenyue Shi, Ana S. H. Costa,……,Michael Potente: “Control of endothelial quiescence byFOXO-regulated metabolites” Nature Cell Biology 2021 DOI 10.1038/s41556-021-00637-6